CIK: 0001766721
Total reported value
$476.3M
Reporting period: 2026-03-31 · Number of holdings: 13
Aisling Capital Management LP disclosed 13 holdings in its latest 13F filing for the period ending 2026-03-31, with total reported value of $476.3M and a quarterly turnover rate of 6.1%.
Browse other institutions with $100M to $1B AUMBrowse other institutions starting with "A"
Aisling Capital Management LP's disclosed holdings carry a Herfindahl concentration index of 0.638 — mathematically equivalent to about 2 equally-sized positions, well below its 13 actual disclosed holdings. That gap points to a strategy built around a small core of high-conviction bets rather than broad diversification.
Position sizes vary widely across the portfolio (a coefficient of variation of 2.81), with a handful of outsized bets alongside many smaller positions.
Recent activity leans toward adding more aggressively to already-large existing positions than to newly initiated ones (a 2.2 percentage-point tilt) — a pattern consistent with a momentum-following approach.
Trim BBIO
0.0% -$11.3M
Add SNDX
0.0% $3.1M
Add GLUE
+5.7% $2.5M
Add BBOT
+80.3% $2.0M
Add BCAX
0.0% $1.7M
Add BMEA
0.0% $594.1K
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | BBIO | Bridgebio Pharma INC | Stock-Healthcare | 79.35% | -1.94% | — | |
| 2 | SNDX | Syndax Pharmaceuticals INC | Stock-Other | 6.46% | +0.68% | — | |
| 3 | GLUE | Monte Rosa Therapeutics INC | Stock-Other | 5.37% | +0.55% | +5.66% | |
| 4 | BCAX | Bicara Therapeutics INC | Stock-Other | 2.38% | +0.38% | — | |
| 5 | BBOT | Bridgebio Oncology Therapeut | Stock-Other | 1.91% | +0.43% | +80.30% | |
| 6 | CMPS | Compass Pathways PLC | Stock-Other | 1.66% | -0.07% | +19.52% | |
| 7 | SRRK | Scholar Rock Holding CORP | Stock-Other | 0.80% | +0.09% | — | |
| 8 | BMEA | Biomea Fusion INC | Stock-Other | 0.66% | +0.13% | — | |
| 9 | EPRX | Eupraxia Pharmaceuticals INC | Stock-Other | 0.49% | +0.49% | NEW | |
| 10 | URGN | UroGen Pharma Ltd. | Stock-Other | 0.41% | -0.12% | — | |
| 11 | ACRS | Aclaris Therapeutics INC | Stock-Other | 0.34% | +0.07% | — | |
| 12 | MRKR | Marker Therapeutics INC | Stock-Other | 0.09% | -0.01% | — | |
| 13 | OKUR | Onkure Therapeutics Inc-a | Stock-Other | 0.08% | +0.03% | — |
Performance for Q3 2026
+15%
Performance Last 4 Quarters
+83.2%
| Period | Holdings | Total value | Stability | Top holdings |
|---|---|---|---|---|
| 2026-03-31 | 13 | $476.3M | 6 | |
| 2025-12-31 | 13 | $478.9M | 38 | |
| 2025-09-30 | 14 | $456.4M | 42 | |
| 2025-06-30 | 13 | $359.7M | 0 | |
| 2025-03-31 | 13 | $288.5M | 100 | |
| 2024-12-31 | 15 | $281.8M | 0 | |
| 2024-09-30 | 16 | $261.1M | 0 | |
| 2024-06-30 | 15 | $231.1M | 0 | |
| 2024-03-31 | 16 | $295.5M | 0 | |
| 2023-12-31 | 16 | $335.2M | 0 | |
| 2023-09-30 | 17 | $242.7M | 0 | |
| 2023-06-30 | 16 | $204.1M | 0 | |
| 2023-03-31 | 16 | $207.8M | 0 | |
| 2022-12-31 | 16 | $151.5M | 0 | |
| 2022-09-30 | 17 | $150.6M | 0 | |
| 2022-06-30 | 19 | $140.2M | 0 | |
| 2022-03-31 | 21 | $185.3M | 0 | |
| 2021-12-31 | 21 | $283.5M | 0 | |
| 2021-09-30 | 21 | $501.5M | 0 | |
| 2021-06-30 | 21 | $624.6M | 100 | |
| 2021-03-31 | 15 | $555.6M | 53 | |
| 2020-12-31 | 16 | $582.3M | 62 | |
| 2020-09-30 | 15 | $313.0M | 31 | |
| 2020-06-30 | 13 | $262.0M | 19 | |
| 2020-03-31 | 14 | $229.6M | 23 | |
| 2019-12-31 | 13 | $261.0M | 45 | |
| 2019-09-30 | 13 | $191.8M | 28 | |
| 2019-06-30 | 14 | $234.1M | 77 | |
| 2019-03-31 | 12 | $131.3M | 39 | |
| 2018-12-31 | 12 | $94.9M | — |
Aisling Capital Management LP's most significant position changes for 2026-03-31: Sold out: Calcimedica INC (CALC); New buy: Eupraxia Pharmaceuticals INC (EPRX); Add: Monte Rosa Therapeutics INC (GLUE) — shares +5.66%; Add: Bridgebio Oncology Therapeut (BBOT) — shares +80.30%; Add: Compass Pathways PLC (CMPS) — shares +19.52%.
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | SNDX | Syndax Pharmaceuticals INC | +0.7% | — | Unchanged |
| 2 | GLUE | Monte Rosa Therapeutics INC | +0.6% | +5.66% | Add |
| 3 | BBOT | Bridgebio Oncology Therapeut | +0.4% | +80.30% | Add |
| 4 | BCAX | Bicara Therapeutics INC | +0.4% | — | Unchanged |
| 5 | BMEA | Biomea Fusion INC | +0.1% | — | Unchanged |
| 6 | SRRK | Scholar Rock Holding CORP | +0.1% | — | Unchanged |
| 7 | ACRS | Aclaris Therapeutics INC | +0.1% | — | Unchanged |
| 8 | OKUR | Onkure Therapeutics Inc-a | 0% | — | Unchanged |
| 9 | MRKR | Marker Therapeutics INC | 0% | — | Unchanged |
| 10 | CMPS | Compass Pathways PLC | -0.1% | +19.52% | Add |
| 11 | URGN | UroGen Pharma Ltd. | -0.1% | — | Unchanged |
| 12 | BBIO | Bridgebio Pharma INC | -1.9% | — | Unchanged |
| 13 | CALC | Calcimedica INC | — | EXIT | Sold out |
| 14 | EPRX | Eupraxia Pharmaceuticals INC | — | NEW | New buy |
| Period | Filed | Type | EDGAR |
|---|---|---|---|
| 2026-03-31 | 2026-05-05 | 13F-HR | View on EDGAR |
| 2025-12-31 | 2026-02-10 | 13F-HR | View on EDGAR |
| 2025-09-30 | 2025-11-12 | 13F-HR | View on EDGAR |
| 2025-06-30 | 2025-08-13 | 13F-HR | View on EDGAR |
| 2025-03-31 | 2025-05-13 | 13F-HR | View on EDGAR |
| 2024-12-31 | 2025-02-12 | 13F-HR | View on EDGAR |
| 2024-09-30 | 2024-11-13 | 13F-HR | View on EDGAR |
| 2024-06-30 | 2024-08-08 | 13F-HR | View on EDGAR |
| 2024-03-31 | 2024-05-14 | 13F-HR | View on EDGAR |
| 2023-12-31 | 2024-02-07 | 13F-HR | View on EDGAR |
| 2023-09-30 | 2023-11-13 | 13F-HR | View on EDGAR |
| 2023-06-30 | 2023-08-11 | 13F-HR | View on EDGAR |
| 2023-03-31 | 2023-05-09 | 13F-HR | View on EDGAR |
| 2022-12-31 | 2023-02-09 | 13F-HR | View on EDGAR |
| 2022-09-30 | 2022-11-03 | 13F-HR | View on EDGAR |
| 2022-06-30 | 2022-08-10 | 13F-HR | View on EDGAR |
| 2022-03-31 | 2022-05-10 | 13F-HR | View on EDGAR |
| 2021-12-31 | 2022-02-18 | 13F-HR | View on EDGAR |
| 2021-09-30 | 2021-11-12 | 13F-HR | View on EDGAR |
| 2021-06-30 | 2021-08-06 | 13F-HR | View on EDGAR |
| 2021-03-31 | 2021-05-14 | 13F-HR | View on EDGAR |
| 2020-12-31 | 2021-02-05 | Amendment | View on EDGAR |
| 2020-12-31 | 2021-02-04 | 13F-HR | View on EDGAR |
| 2020-09-30 | 2020-11-12 | 13F-HR | View on EDGAR |
| 2020-06-30 | 2020-08-10 | 13F-HR | View on EDGAR |
| 2020-03-31 | 2020-05-11 | 13F-HR | View on EDGAR |
| 2019-12-31 | 2020-02-06 | 13F-HR | View on EDGAR |
| 2019-09-30 | 2019-11-13 | 13F-HR | View on EDGAR |
| 2019-06-30 | 2019-08-13 | Amendment | View on EDGAR |
| 2019-06-30 | 2019-08-08 | 13F-HR | View on EDGAR |
| 2019-03-31 | 2019-05-20 | 13F-HR | View on EDGAR |
| 2018-12-31 | 2019-02-08 | 13F-HR | View on EDGAR |
Institutions with a similar AUM
CIK 0001569765
Total reported value
$476.0M
199 stks
2026-03-31
AUM within 0.1% of this institution
CIK 0001527782
Total reported value
$476.0M
186 stks
2022-12-31
Stale — no recent filing
AUM within 0.1% of this institution
CIK 0001733777
Total reported value
$476.0M
186 stks
2022-12-31
Stale — no recent filing
AUM within 0.1% of this institution
Institutions with overlapping top holdings
CIK 0001637359
Total reported value
$163.1M
10 stks
2026-03-31
2 of the top 5 holdings overlap, including Bicara Therapeutics INC
CIK 0001892770
Total reported value
$168.0M
88 stks
2026-03-31
2 of the top 5 holdings overlap, including Syndax Pharmaceuticals INC
CIK 0001958125
Total reported value
$478.7M
41 stks
2026-03-31
2 of the top 5 holdings overlap, including Bridgebio Pharma INC